Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV

2019; American Medical Association; Volume: 2; Issue: 11 Linguagem: Inglês

10.1001/jamanetworkopen.2019.14816

ISSN

2574-3805

Autores

Hadas Sorotsky, David Hogg, Eitan Amir, Daniel Vilarim Araújo,

Tópico(s)

Pneumocystis jirovecii pneumonia detection and treatment

Resumo

a group with intact immunological function and survival in keeping with the general population.In contrast, the exclusion of PLWH is unsupported by current data, denies patients the benefit of ICI therapy, and is ethically unjustifiable.We advocate for a broader inclusion of these patients in oncology trials.

Referência(s)